You are here

ADVANCED DIAGNOSTICS USING RNA/PROTEIN FUSION TECHNOLOGY

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44AI046106-03
Agency Tracking Number: AI046106
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PHYLOS, INC. 128 SPRING ST
LEXINGTON, MA 02421
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRENT KREIDER
 (617) 995-2838
 BKREIDER@AKCELI.COM
Business Contact
 ANNE BAIA
Phone: (781) 862-6400
Email: ABAIA@PHYLOS.COM
Research Institution
N/A
Abstract

The objective of this project is to develop advanced diagnostic and therapeutic monitoring systems for agents involved in allergy and inflammation. A key initiative in NIAID programs for Healthy People 2010 is the development of tools for drug discovery and monitoring allergy and inflammation that are associated with infectious disease and chronic disabling conditions. Cytokines and chemokines are mediators (or surrogate markers) of these disease processes. In this program, a novel immunoglobulin-like scaffold has been developed as an antibody mimic. From a large random library consisting of 10313-10e14 distinct members, binding proteins were rapidly selected in vitro against key mediators by inflammatory or allergic processes. Antibody mimics to a minimum of 5 cytokine or chemokine targets were selected and will be further evaluated for performance characteristics such as affinity, specificity, epitope mapping, and ability to function on a solid phase surface. If needed, binding proteins can be improved by affinity maturation, and PCR mutagenesis. The resulting antibody-mimics will be used for the development of a prototype addressable protein chip for detection of these markers in a variety of experimental samples. This multiplex microarray will be validated for the detection and quantification of cytokines and/or chemokines in culture supernatants, biological fluids, cells, or tissues. PROPOSED COMMERCIAL APPLICATIONS: This technology provides a powerful alternative to monoclonal antibodies and phage display mediated production of antibodies or fragments thereof. These unique protein binders will be incorporated into an addressable multiplex array for the high throughput analysis of samples from culture supernatants, biological fluids or cells for drug discovery and diagnostic applications.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government